Unique to the human species is the ability to think, to reason logically, and to remember, in detail, events of the past. But the brain is fragile, and when disrupted, the loss of cognitive functioning—thinking, remembering, and reasoning—to such an extent that it interferes with a person’s daily life and activities poses a major concern.
Dementia or Alzheimer’s Disease, the most common form of dementia, ensues. An estimated 5 million Americans are living with Alzheimer’s Disease. This number is expected to double approximately every twenty years. In May 2010, Alzheimer’s disease became the sixth-leading leading cause of death, according to the Centers for Disease Control and Prevention (CDC).
But, Pico-Tesla, Magnetic Therapies, a medical research and device development company that has designed, patented and manufactured therapeutic systems that provide a platform technology to address both Parkinson’s and Alzheimer’s Disease may offer hope for the masses. Their system (the Resonator™ device) utilizes precisely tuned, extremely low level electromagnetic fields that are applied to the body for therapeutic intervention of disease or illness. A key advantage of this therapy is that it is non-invasive, non-drug, and non-significant risk.
Pico-Tesla has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have Alzheimer’s disease symptoms. The pilot study seeks to determine whether the application of magnetic fields generated by Pico-Tesla’s patented Resonator™ system can be effective as an adjunctive therapy to oral medications in reducing the symptoms of Alzheimer’s disease.
The study will be coordinated by Amanda Grant Smith, M.D., Medical Director of the USF Health Byrd Alzheimer’s Institute, University of South Florida (USF).
The theory as to how the Resonator™ device functions can in part be explained by well-accepted principles of Quantum physics and biology. The MRI device alters the atoms in the body with a very powerful magnet, in such a dramatic manner as to be able to obtain an image of the body. In contrast, the Resonator™ device utilizes the same principle, albeit at targeted field strengths of a much lower level.
Disease states of any type (e.g. infection, nutritional deficiencies, genetic defects, toxic exposures and injuries) induce not only observed macroscopic changes in tissue, but also have molecular, submolecular and atomic consequences as well. In a diseased, Pico –Tesla suggests that the affected area’s atoms and their electromagnetic fields are altered, leading to inevitable lost efficiencies in cellular function and communication.
Determining the appropriate magnetic field strength of a therapy is based on calculations derived from the Jacobson Resonance™ equation. This method starts with:
• Choosing the correct molecular target(s) for the disease state in question
• Determining the molecular weight of these target molecule(s)
These variables dictate the magnetic field’s strength and frequency to be applied. Because these molecular targets are extremely small magnets themselves, the appropriate magnetic field to be applied by the Resonator™ device must also be extremely small.
New in-demand reports on health care equipment markets elaborated by Datamonitor are available in its catalogue. The report uncovers value of the Alzheimer’s disease market across the seven major markets that is forecast to reach $11.9 billion by 2019. The study shares the commercial prospects of potentially disease-modifying therapies in Alzheimer’s disease patients over the next 10 years.
Pico-Tesla was a presenting company at OneMedForum SF 2011.